We’re Making History!
Anika History
2021
WristMotion® Total Wrist Arthroplasty System launched for the replacement of painful wrist joints.
FDA 510(k) clearance received for Tactoset® Injectable Bone Substitute to include a new indication for augmentation of hardware, including suture anchors.
Competed enrollment for US pilot clinical study of Cingal®, a combination hyaluronic acid (HA) and fast-acting steroid injection for osteoarthritis knee pain.
Hosted an Investor Day, which detailed Anika’s multi-year strategy and roadmap of becoming a global leader in joint preservation and restoration.
2020
Anika acquired Arthrosurface, a leading, privately-held provider of joint preservation solutions, and Parcus Medical, a leading, privately-held sports medicine company.
Cheryl R. Blanchard, Ph.D., appointed as President and Chief Executive Officer.
FDA 510(k) clearance received for its WristMotion Total Wrist Arthroplasty (TWA) System.
FDA 501(k) clearance received for Actiflip, a button fixation system for biceps tenodesis.
2019
Tactoset was launched in the United States, a surgically delivered therapy for insufficiency fractures.
510(k) clearance received for the company’s first suture anchors comprised of biocomposite material bTCP/PLGA2.
FDA clearance received for Synd-EZ Kits for ankle syndesmosis repair2.
ATLAS (Anatomic Thumb Ligament Arthroplasty System), a more anatomical and less invasive arthroplasty solution to treat arthritis of the CMC joint (thumb), gained 501(k) clearance2.
2017
FDA 510(k) clearance received for HA-enhanced Tactoset Injectable Bone Substitute for the treatment of insufficiency fractures.
501(k) clearance received for Slik Knotless Screw-In Suture Anchors and Slik Fix Tenodesis System2
2016
International launch of Cingal, the first HA-based viscosupplement plus steroid combination product for the treatment of osteoarthritis pain.
510(k) clearance received for the GFS Ultimate adjustable suture loop, further expanding the portfolio of graft fixation system (GFS) products2.
First surgery performed using the company’s first tissue-based product, the Glenojet® Allograft System for shoulder glenoid reconstruction1.
CE Mark approval received for Orthovisc®-T, a treatment designed to relieve pain and restore function for patients with chronic tennis elbow.
2015
Entered the hand & wrist market with the WristMotion Hemiarthroplasty Implant1.
A larger 5x5cm Hyalofast® scaffold to treat large cartilage defects was introduced internationally.
2013
FDA clearance received for Draw Tight, an innovative suture-based anchor for use in both large and small joint repairs2.
2011
First surgery performed using the anatomic OVO® implant for the treatment of glenohumeral osteoarthritis (OA) 1.
2010
Received CE mark certification and launched its first sports medicine soft tissue repair solutions in the European Union2.
2009
Acquired technology used in Hyalofast, a one-step cartilage regeneration product, through the strategic acquisition of Fidia Advanced Biopolymers, a leading innovator in hyaluronic acid-based tissue engineered products, based in Abano Terme, Italy.
Hyalofast received CE mark approval and launched internationally.
Received 510(k) clearance for the first PEEK CF (carbon fiber reinforced polyetheretherketone) suture anchors and interference screws used in sports medicine2.
First surgery performed using the Arthrosurface Toe HemiCAP® DF, its third anatomic foot & ankle implant brought to market since entering the foot & ankle space in 20051.
First surgery performed using the anatomic PF Wave® knee implant1.
First 510(k) clearances received for titanium soft tissue fixation devices2.
2007
CE mark approval received for Monovisc in Europe.
Parcus Medical, LLC was founded by partners with extensive orthopedic industry experience2.
2004
Obtained FDA approval for and launched Orthovisc in the United States.
First international anatomic joint preservation implant surgeries performed in the knee and shoulder1.
2003
First anatomic joint preservation implant surgeries performed in the shoulder in the United States1.
Established a marketing and distribution relationship with Johnson & Johnson to sell Orthovisc in the United States once approved by the FDA.
2001
Arthrosurface was founded and incorporated1.
1996
Received CE mark approval for and launched Orthovisc internationally, the company’s first HA-based viscosupplement used for the treatment of osteoarthritis pain.
1995
Signed a distribution agreement with Boehringer Ingelheim Vetmedica for its HA-based equine osteoarthritis product, Hyvisc®, a partnership that has continued to this day.
1992
Anika Therapeutics was incorporated as a spin-off of MedChem Products, Inc.
Signed an agreement with Johnson & Johnson to manufacture and supply its hyaluronic acid-based ophthalmic products, Amvisc® and Amvisc® Plus.
- Brought to Anika through the acquisition of Arthrosurface, Inc.
- Brought to Anika through the acquisition of Parcus Medical LLC